[go: up one dir, main page]

MX2017013881A - Composiciones y metodos para la vigilancia activa del cancer de prostata. - Google Patents

Composiciones y metodos para la vigilancia activa del cancer de prostata.

Info

Publication number
MX2017013881A
MX2017013881A MX2017013881A MX2017013881A MX2017013881A MX 2017013881 A MX2017013881 A MX 2017013881A MX 2017013881 A MX2017013881 A MX 2017013881A MX 2017013881 A MX2017013881 A MX 2017013881A MX 2017013881 A MX2017013881 A MX 2017013881A
Authority
MX
Mexico
Prior art keywords
prostate cancer
methods
compositions
active surveillance
surveillance
Prior art date
Application number
MX2017013881A
Other languages
English (en)
Inventor
j vickers Andrew
T Scardino Peter
Lilja Hans
Dong Yan
SJOBERG Daniel
Original Assignee
Opko Diagnostics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Diagnostics Llc filed Critical Opko Diagnostics Llc
Publication of MX2017013881A publication Critical patent/MX2017013881A/es

Links

Classifications

    • G01N33/57555—
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Theoretical Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Data Mining & Analysis (AREA)
  • Molecular Biology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Software Systems (AREA)
  • Mathematical Physics (AREA)
  • Computing Systems (AREA)
  • Pure & Applied Mathematics (AREA)
  • Mathematical Optimization (AREA)
  • Mathematical Analysis (AREA)
  • Evolutionary Computation (AREA)
  • Computational Mathematics (AREA)
  • Artificial Intelligence (AREA)
  • Algebra (AREA)
  • Probability & Statistics with Applications (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Immunology (AREA)

Abstract

Aspectos de la divulgación se refieren a métodos y sistemas mejorados para la vigilancia activa de un sujeto que tiene cáncer de próstata no agresivo.
MX2017013881A 2015-04-29 2016-04-29 Composiciones y metodos para la vigilancia activa del cancer de prostata. MX2017013881A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154616P 2015-04-29 2015-04-29
PCT/US2016/029959 WO2016176529A1 (en) 2015-04-29 2016-04-29 Compositions and methods for active surveillance of prostate cancer

Publications (1)

Publication Number Publication Date
MX2017013881A true MX2017013881A (es) 2018-03-12

Family

ID=57198800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013881A MX2017013881A (es) 2015-04-29 2016-04-29 Composiciones y metodos para la vigilancia activa del cancer de prostata.

Country Status (20)

Country Link
US (2) US20160320394A1 (es)
EP (2) EP3287786A3 (es)
JP (1) JP6873916B2 (es)
KR (1) KR102527446B1 (es)
CN (1) CN107530412A (es)
AU (1) AU2016254127B2 (es)
CA (1) CA2982262A1 (es)
CL (1) CL2017002701A1 (es)
CO (1) CO2017010808A2 (es)
DE (1) DE202016008673U1 (es)
EA (1) EA039028B1 (es)
HK (2) HK1247824A1 (es)
IL (1) IL254833B (es)
MX (1) MX2017013881A (es)
MY (1) MY197117A (es)
PE (1) PE20180930A1 (es)
SG (1) SG11201708289TA (es)
TW (1) TWI766836B (es)
UA (1) UA125745C2 (es)
WO (1) WO2016176529A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202010018623U1 (de) 2009-02-02 2018-12-07 Opko Diagnostics, Llc Strukturen zur Steuerung der Lichtwechselwirkung mit mikrofluidischen Vorrichtungen
PE20150333A1 (es) 2012-03-05 2015-03-25 Arctic Partners Ab Oy Metodos y aparatos para predecir riesgo de cancer de prostata y volumen de glandula prostatica
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
HUE065029T2 (hu) 2014-03-28 2024-04-28 Opko Diagnostics Llc A prosztatarák diagnosztikával kapcsolatos készítmények és eljárások
UA124522C2 (uk) 2015-03-27 2021-10-05 Опко Дайегностікс, Елелсі Спосіб кількісної оцінки рівнів простатичного антигену
US10852310B2 (en) 2015-12-11 2020-12-01 Opko Diagnostics, Llc Fluidic systems involving incubation of samples and/or reagents
PL3397387T3 (pl) 2015-12-29 2021-11-22 Opko Diagnostics, Llc Urządzenie do zbierania płynów i związane z nim metody
WO2019221930A1 (en) * 2018-05-16 2019-11-21 Opko Diagnostics, Llc Methods for detecting prostate cancer pathology associated with adverse outcomes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211397B2 (en) * 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
FI20002127A0 (fi) * 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
WO2011027310A1 (en) * 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
US8932523B2 (en) 2010-04-16 2015-01-13 Opko Diagnostics, Llc Systems and devices for analysis of samples
PE20150333A1 (es) * 2012-03-05 2015-03-25 Arctic Partners Ab Oy Metodos y aparatos para predecir riesgo de cancer de prostata y volumen de glandula prostatica
WO2013172779A2 (en) 2012-05-16 2013-11-21 Phadia Ab Method for indicating the presence or non-presence of prostate cancer
AU2013349721B2 (en) * 2012-11-20 2019-03-28 A3P Biomedical Ab Prognostic method for individuals with prostate cancer
EP2922967B1 (en) * 2012-11-20 2018-01-03 Phadia AB Method for indicating a presence or non-presence of aggressive prostate cancer

Also Published As

Publication number Publication date
CA2982262A1 (en) 2016-11-03
EP3247387A1 (en) 2017-11-29
IL254833B (en) 2021-12-01
HK1247824A1 (zh) 2018-10-05
EP3247387A4 (en) 2018-09-12
EA039028B1 (ru) 2021-11-24
MY197117A (en) 2023-05-26
IL254833A0 (en) 2017-12-31
HK1247559A1 (zh) 2018-09-28
KR20180018514A (ko) 2018-02-21
US20160320394A1 (en) 2016-11-03
TW201705028A (zh) 2017-02-01
TWI766836B (zh) 2022-06-11
AU2016254127B2 (en) 2022-05-26
EA201792372A1 (ru) 2018-03-30
JP2018518661A (ja) 2018-07-12
CO2017010808A2 (es) 2018-04-19
CN107530412A (zh) 2018-01-02
KR102527446B1 (ko) 2023-05-02
US20220399121A1 (en) 2022-12-15
UA125745C2 (uk) 2022-06-01
AU2016254127A1 (en) 2017-10-26
CL2017002701A1 (es) 2018-07-06
SG11201708289TA (en) 2017-11-29
BR112017022391A2 (pt) 2018-07-10
WO2016176529A1 (en) 2016-11-03
PE20180930A1 (es) 2018-06-08
EP3287786A3 (en) 2018-03-21
DE202016008673U1 (de) 2019-01-22
EP3287786A2 (en) 2018-02-28
JP6873916B2 (ja) 2021-05-19

Similar Documents

Publication Publication Date Title
PH12020551397A1 (en) Cot modulators and methods of use thereof
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
MX2017013881A (es) Composiciones y metodos para la vigilancia activa del cancer de prostata.
MX2018006767A (es) Composiciones y metodos para oncologia inmunologica.
MY190297A (en) Anti-pd1 antibodies and methods of use
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
MY184870A (en) Immunomodulators
PH12016501763A1 (en) Multispecific antibodies
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
MX370807B (es) Anticuerpos que se unen a axl.
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
MX2021010460A (es) Metodo de tratamiento con tradipitant.
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
MX383748B (es) Procesos para la preparación de un compuesto de diariltiohidantoína.
MX363677B (es) Sistemas fotovoltaicos y procesos de revestimiento por aspersion para producir sistemas fotovoltaicos.
GB2569488A (en) PD-1 specific aptamers
MY187959A (en) Reactor
DOP2017000264A (es) Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio
MX2016004573A (es) Inhibidores de nsp4 y metodos de uso.
CL2017002653A1 (es) Procedimiento y reactor para fijar arsénico.
EA201691203A1 (ru) Твёрдые формы тенофовира
MX375999B (es) Metodo para producir polvo hidraulico.
MX2017001929A (es) Activacion del factor x.